Abstract
Acute thrombotic microangiopathy (TMA) developing in association with SARS-CoV-2 infection is a rare but recognized phenomenon in native kidneys. In the allograft kidney, a diagnosis of TMA has a broad etiologic differential, including antibody-mediated rejection and recurrent and de novo causes of TMA that affect the native kidney. Prior case reports have described plasma exchange or eculizumab use in patients with COVID-19–associated TMA. Herein, we describe the course of a kidney transplant patient with COVID-19–associated TMA with response to eculizumab that was sustained after medication withdrawal and review the literature on COVID-19–associated TMA of the allograft kidney.
Original language | English (US) |
---|---|
Pages (from-to) | 1866-1869 |
Number of pages | 4 |
Journal | Transplantation proceedings |
Volume | 55 |
Issue number | 8 |
DOIs | |
State | Published - Oct 2023 |
ASJC Scopus subject areas
- Surgery
- Transplantation